公开(公告)号：WO2004060859A3

公开(公告)日：2004-09-02

申请号：PCT/US0338906

申请日：2003-12-08

Applicant: ABBOTT LAB

Inventor： ANDERSON STEVEN N ,  BHATIA PRAMILA ,  KOLASA TEODOZYJ ,  NAKANE MASAKI ,  PATEL MEENA V ,  ROHDE JEFFREY J ,  XIA ZHIREN ,  ZHANG HENRY Q

IPC: C07C323/62 ,  C07D211/16 ,  C07D211/34 ,  C07D211/42 ,  C07D211/46 ,  C07D211/62 ,  C07D213/70 ,  A61K31/165 ,  A61K31/44

CPC classification number: C07D213/70 ,  C07C323/62 ,  C07D211/16 ,  C07D211/34 ,  C07D211/42 ,  C07D211/46 ,  C07D211/62

Abstract: Compounds of formula (I) are useful for increasing cGMP levels in a mammal.

Abstract translation: 式（I）化合物可用于增加哺乳动物中的cGMP水平。

公开(公告)号：WO9717085A3

公开(公告)日：1997-08-07

申请号：PCT/US9617860

申请日：1996-11-06

Applicant: ABBOTT LAB

Inventor： MUKERJI PRADIP ,  THURMOND JENNIFER M ,  HANSSON LENNART ,  BAXTER JEFFREY H ,  HARDS ROBERT G ,  LEONARD AMANDA EUN-YEONG ,  ANDERSON STEVEN N ,  HARVEY LINDA A

IPC: C12N15/09 ,  A23L1/305 ,  A61K31/00 ,  A61K38/00 ,  A61P27/00 ,  A61P27/16 ,  A61P31/00 ,  A61P31/04 ,  C07K14/47 ,  A61K38/17

CPC classification number: C07K14/4732 ,  A23L33/19 ,  A61K38/00

Abstract: A method is provided for inhibiting the attachment of H. influenzae to human cells, such as pharyngeal cells, by contacting the bacilli with phosphorylated recombinant human β-casein that have at least 3 phosphate groups. A product containing phosphorylated recombinant human β-casein may be a liquid enteral nutritional product such as infant formula. The enteral nutritional product may be used for the prevention and treatment of otitis media in infants. The phosphorylated recombinant human β-casein may also be administered as a throat spray or used in nose drops or a spray.

公开(公告)号：CA2257412A1

公开(公告)日：1998-02-05

申请号：CA2257412

申请日：1997-07-23

Applicant: ABBOTT LAB

Inventor： SCHALLER JOSEPH ,  LEE THERESA SIU-LING WAI ,  ANDERSON STEVEN N ,  LIU JIN-ZHOU ,  MAZER TERRY BRUCE ,  HILTY MILO DUANE ,  GUZMAN-HARTY MELINDA

IPC: A61P31/12 ,  A61K31/225 ,  A61P31/04 ,  C07C69/70 ,  C07C305/06 ,  C07F9/09

Abstract: The present invention provides water-miscible lipid derivatives effective to inhibit the infectious activity of pathogenic microorganisms. Preferred watermiscible lipid derivatives are diacetyltartaric acid esters of monoglycerides wherein 90 percent or more of the fatty acid content is accounted for by a single fatty acid. The fatty acid component preferably contains from 8 to 24 and, more preferably, from about 10 to about 20 carbon atoms. The fatty acid can be saturated, unsaturated or hydroxylated.

公开(公告)号：CA2257421A1

公开(公告)日：1998-02-05

申请号：CA2257421

申请日：1997-07-23

Applicant: ABBOTT LAB

Inventor： LIU JIN-ZHOU ,  LAMM JILL M ,  MAZER TERRY B ,  BOWMAN TAMMY MARIE ,  LEE THERESA SIU-LING WAI ,  ANDERSON STEVEN N ,  GUZMAN-HARTY MELINDA ,  HILTY MILO DUANE ,  SCHALLER JOSEPH

IPC: A23L1/30 ,  A61K31/22 ,  A61K31/23 ,  A61P31/12 ,  A61P31/16 ,  A61P31/18 ,  A61P31/22

Abstract: A nutritional formulation containing an amount of diacetyltartaric acid esters of mono- and diglycerides effective to inhibit the infectious activity of pathogenic microorganisms is provided. A method of inhibiting the infectious activity of pathogenic microorganisms including the step of feeding the nutritional composition to a subject is also provided.

公开(公告)号：CA2234664A1

公开(公告)日：1997-05-15

申请号：CA2234664

申请日：1996-11-06

Applicant: ABBOTT LAB ,  SYMBICOM AB

Inventor： THURMOND JENNIFER M ,  HANSSON LENNART ,  MUKERJI PRADIP ,  BAXTER JEFFREY H ,  ANDERSON STEVEN N ,  HARVEY LINDA A ,  LEONARD AMANDA EUN-YEONG ,  HARDS ROBERT G

IPC: A23C9/152 ,  A23C9/20 ,  A23L33/18 ,  A61K38/17 ,  C07K14/47 ,  C12N15/12 ,  C12N15/63 ,  C12P21/02 ,  A23L1/305

Abstract: A method is provided for inhibiting the attachment of H. influenzae to human cells, such as pharyngeal cells, by contacting the bacilli with phosphorylated recombinant human .beta.-casein that have at least 3 phosphate groups. A product containing phosphorylated recombinant human .beta.-casein may be a liquid enteral nutritional product such as infant formula. The enteral nutritional product may be used for the prevention and treatment of otitis media in infants. The phosphorylated recombinant human .beta.-casein may also be administered as a throat spray or used in nose drops or a spray.

公开(公告)号：ES2185975T3

公开(公告)日：2003-05-01

申请号：ES97936999

申请日：1997-07-23

Applicant: ABBOTT LAB

Inventor： MAZER TERRY BRUCE ,  ANDERSON STEVEN N ,  GUZMAN-HARTY MELINDA ,  HILTY MILO DUANE ,  LEE THERESA SIU-LING WAI ,  SHALLER JOSEPH

IPC: A61P31/12 ,  A61K31/225 ,  A61P31/04 ,  C07C69/70

Abstract: The present invention provides water-miscible lipid derivatives effective to inhibit the infectious activity of pathogenic microorganisms. Preferred water-miscible lipid derivatives are diacetyltartaric acid esters of monoglycerides wherein 90 percent or more of the fatty acid content is accounted for by a single fatty acid. The fatty acid component preferably contains from 8 to 24 and, more preferably, from about 10 to about 20 carbon atoms. The fatty acid can be saturated, unsaturated or hydroxylated.

公开(公告)号：AT224355T

公开(公告)日：2002-10-15

申请号：AT97936999

申请日：1997-07-23

Applicant: ABBOTT LAB

Inventor： MAZER TERRY BRUCE ,  ANDERSON STEVEN N ,  GUZMAN-HARTY MELINDA ,  HILTY MILO DUANE ,  LEE THERESA SIU ,  SHALLER JOSEPH ,  LIU JIN-ZHOU

IPC: A61P31/12 ,  A61K31/225 ,  A61P31/04 ,  C07C69/70

Abstract: The present invention provides water-miscible lipid derivatives effective to inhibit the infectious activity of pathogenic microorganisms. Preferred water-miscible lipid derivatives are diacetyltartaric acid esters of monoglycerides wherein 90 percent or more of the fatty acid content is accounted for by a single fatty acid. The fatty acid component preferably contains from 8 to 24 and, more preferably, from about 10 to about 20 carbon atoms. The fatty acid can be saturated, unsaturated or hydroxylated.

公开(公告)号：PT918742E

公开(公告)日：2003-02-28

申请号：PT97936999

申请日：1997-07-23

Applicant: ABBOTT LAB

Inventor： LIU JIN-ZHOU ,  MAZER TERRY BRUCE ,  ANDERSON STEVEN N ,  GUZMAN-HARTY MELINDA ,  HILTY MILO DUANE ,  LEE THERESA SIU-LING WAI ,  SHALLER JOSEPH

IPC: A61K31/225 ,  A61P31/04 ,  A61P31/12 ,  C07C69/70

Abstract: The present invention provides water-miscible lipid derivatives effective to inhibit the infectious activity of pathogenic microorganisms. Preferred water-miscible lipid derivatives are diacetyltartaric acid esters of monoglycerides wherein 90 percent or more of the fatty acid content is accounted for by a single fatty acid. The fatty acid component preferably contains from 8 to 24 and, more preferably, from about 10 to about 20 carbon atoms. The fatty acid can be saturated, unsaturated or hydroxylated.

公开(公告)号：DK0918742T3

公开(公告)日：2002-12-09

申请号：DK97936999

申请日：1997-07-23

Applicant: ABBOTT LAB

Inventor： MAZER TERRY BRUCE ,  ANDERSON STEVEN N ,  GUZMAN-HARTY MELINDA ,  LEE THERESA SIU-LING WAI ,  SHALLER JOSEPH ,  LIU JIN-ZHOU ,  HILTY MILO DUANE

IPC: A61P31/12 ,  A61K31/225 ,  A61P31/04 ,  C07C69/70

Abstract: The present invention provides water-miscible lipid derivatives effective to inhibit the infectious activity of pathogenic microorganisms. Preferred water-miscible lipid derivatives are diacetyltartaric acid esters of monoglycerides wherein 90 percent or more of the fatty acid content is accounted for by a single fatty acid. The fatty acid component preferably contains from 8 to 24 and, more preferably, from about 10 to about 20 carbon atoms. The fatty acid can be saturated, unsaturated or hydroxylated.

公开(公告)号：NZ322369A

公开(公告)日：1999-11-29

申请号：NZ32236996

申请日：1996-11-06

Applicant: ABBOTT LAB ,  SYMBICOM AB

Inventor： MUKERJI PRADIP ,  THURMOND JENNIFER M ,  HANSSON LENNART ,  BAXTER JEFFREY H ,  HARDS ROBERT G ,  LEONARD AMANDA EUN-YEONG ,  ANDERSON STEVEN N ,  HARVEY LINDA A

IPC: C12N15/09 ,  A23L1/305 ,  A61K31/00 ,  A61K38/00 ,  A61P27/00 ,  A61P27/16 ,  A61P31/00 ,  A61P31/04 ,  C07K14/47 ,  A61K38/17 ,  A23C11/08

Abstract: A method is provided for inhibiting the attachment of Haemophilus influenzae to human pharyngeal cells by contacting the bacilli with phosphorylated recombinant human b-casein that have at least 3 phosphate groups. A product containing phosphorylated recombinant human b-casein may be a liquid enteral nutritional product such as infant formula. The enteral nutritional product may be used for the prevention and treatment of otis media in infants. The phosphorylated recombinant human b-casein may also be administrated as a throat spray or used in nose drops or spray.